{"filings":[{"id":2244000,"accession_number":"0001552781-26-000441","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-08-13T20:05:44+00:00","items":["5.02"],"status":"ready","headline":"Omeros appoints Joseph Schocken to board, expands to nine directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to nine directors; Joseph Schocken appointed effective Aug 12, 2026.","Schocken, 79, founder of Tranceka Capital, joins Audit Committee; term to 2027 annual meeting.","Granted option for 30,000 shares under non-employee director compensation policy.","No material interest in transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2216924,"accession_number":"0001437749-26-027313","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-08-12T20:09:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.","GAAP net income $13.2M ($0.18/sh) vs $56.1M ($0.78) in Q1; non-GAAP adjusted net income $1.8M ($0.02) vs -$17.1M ($0.24).","Cash and short-term investments $132.0M at June 30, 2026; Q2 operating cash flow $4.1M.","In July, repurchased $30.5M principal of 2029 notes for $60.2M, cutting outstanding to $40.3M and conversion shares from ~11.4M to 6.5M.","CHMP negative opinion on narsoplimab MAA for TA-TMA in June; re-examination requested. J-code effective July 1, NTAP effective Oct 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1750317,"accession_number":"0001437749-26-023886","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-07-20T21:05:11+00:00","items":["8.01"],"status":"ready","headline":"Omeros repurchases $14.5M of convertible notes; total $30.5M retired, $40.3M remains","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased $14.5M principal of 9.50% Convertible Senior Notes due 2029 for ~$29.0M total (incl. accrued interest).","Combined with prior $16.0M repurchase, total retired $30.5M principal amount of Notes.","Approximately $40.3M principal amount of Notes remains outstanding after repurchases.","Repurchases were under privately negotiated agreements with certain holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1454159,"accession_number":"0001552781-26-000377","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-07-06T12:30:27+00:00","items":["8.01"],"status":"ready","headline":"Omeros to repurchase additional $14.5M of 9.50% Convertible Notes due 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Previously disclosed repurchase of $16.0M principal for ~$31.3M expected to close July 6, 2026.","New agreements to repurchase up to $14.5M additional principal for up to ~$31.0M, closing July 20-30, 2026.","After both repurchases, ~$40.3M principal of Notes will remain outstanding.","Company may seek unsecured or limited-collateral debt financing to replace cash used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1258156,"accession_number":"0001437749-26-021617","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-06-25T10:02:47+00:00","items":["5.07"],"status":"ready","headline":"Omeros shareholders elect three Class II directors, approve compensation and incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas J. Cable, Peter A. Demopulos, and Diana T. Perkinson elected as Class II directors to 2029 term; votes ranged from 20.8M to 25.3M for.","Advisory vote on named executive officer compensation approved: 24.4M for, 6.9M against, 507K abstain.","Amended omnibus incentive compensation plan approved: 19.1M for, 12.2M against, 448K abstain.","Ratification of Ernst & Young as auditor for FY 2026: 53.1M for, 4.4M against, 504K abstain.","Meeting had 58.0M shares (80.04%) represented out of 72.2M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1120717,"accession_number":"0001437749-26-021040","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-06-18T11:52:18+00:00","items":["8.01"],"status":"ready","headline":"Omeros to repurchase up to $16M principal of 9.50% Convertible Notes for ~$34M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchase of up to $16.0M aggregate principal amount of 9.50% Convertible Senior Notes due 2029.","Total purchase price up to ~$34.0M, including accrued interest, subject to adjustment based on common stock trading price.","Expected closing between July 6 and July 16, 2026.","After repurchase, approximately $54.8M principal amount of Notes will remain outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68041,"accession_number":"0001437749-26-016718","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-05-13T20:06:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net income $56.1M on $73.1M non-cash gain; YARTEMLEA net sales $9.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $56.1M ($0.78/share) vs. net loss $33.5M ($0.58) in Q1 2025; includes $73.1M non-cash gain on embedded derivatives.","Non-GAAP adjusted net loss $17.1M ($0.24/share); total operating expenses fell 22% to $27.3M.","YARTEMLEA launch in Jan 2026: gross sales $11.1M, net sales $9.9M; CMS assigned J-code (eff. July 1) and recommended NTAP (eff. Oct 1).","Cash and short-term investments $135.3M; repaid $17.1M 2026 Notes; only $70.8M 2029 Notes remain (mature June 2029).","Repurchased 0.4M shares at avg $11.70 for $4.2M; MAA for YARTEMLEA under EMA review with decision expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":9893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102343,"accession_number":"0001437749-26-010634","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).","Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.","FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.","Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.","Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M."],"consensus_eps_estimate":-0.3264,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":9893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102342,"accession_number":"0001437749-26-000820","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Omeros reports preliminary cash and short-term investments of $171.5M at year-end 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash and short-term investments of $171.5M as of Dec 31, 2025.","Figure is preliminary and subject to completion of customary closing procedures.","Disclosed during investor conference call on January 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118622,"accession_number":"0001437749-25-038758","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"FDA approves Omeros' YARTEMLEA as first therapy for TA-TMA; launch set for Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["YARTEMLEA (narsoplimab-wuug) approved for adults and children ≥2 years with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).","Pivotal trial CR rate 61%, EAP CR rate 68%; 100-day survival 73% and 74% respectively; all patients high-risk.","No Boxed Warning or REMS; most common adverse reactions (≥20%) include viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue, hypokalemia.","U.S. launch planned for January 2026; dedicated ICD-10 and procedure codes in place; YARTEMLEAssist patient support program expected in Q1 2026.","Marketing authorization application under EMA review with decision expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118621,"accession_number":"0001437749-25-036507","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.02","2.01","9.01"],"status":"ready","headline":"Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.","Used $72.6M of proceeds to repay $67.1M term loan, prepayment premium, interest; Credit Agreement terminated.","Board authorized up to $100M share repurchase program for common stock with indefinite term.","Remaining cash expected to fund >12 months of operations, including narsoplimab launch for TA-TMA.","Pro forma financials show net income of $124.4M for FY2024 and net loss of $69.9M for 9M2025 after asset sale adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118620,"accession_number":"0001437749-25-034824","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).","Entered up to $2.1B asset purchase/license deal with Novo Nordisk for zaltenibart; $240M upfront at Q4 2025 close.","Cash $36.1M at Sep 30; Q3 cash burn $22M ex-financing; raised $20.3M from Polar and $9M from ATM in Q3.","PDUFA date for narsoplimab in TA-TMA extended to Dec 26, 2025; commercial launch team ready with brand YARTEMLEA.","OMIDRIA royalties $9.2M in Q3 on net sales of $30.5M; operating expenses fell to $26.4M from $35.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118619,"accession_number":"0001437749-25-030968","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.","Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.","Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.","Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135105,"accession_number":"0001437749-25-026931","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.","Post-quarter: raised $20.6M net from Polar Asset Management (5.37M shares at $4.10, 14% premium) plus $2.1M from ATM.","Narsoplimab BLA PDUFA date extended to Dec 26, 2025; FDA expects labeling talks by Oct. EMA MAA validated, opinion mid-2026.","Exchanged $70.8M of 2026 Notes for 2029 Notes; remaining 2026 Notes reduced to $17.1M; avoided $20M prepayment on term debt.","In talks for potential asset deal with multi-billion total value; upfront cash would repay $67.1M term loan and $17.1M notes."],"consensus_eps_estimate":-0.4906,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135104,"accession_number":"0001104659-25-070554","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.","Narsoplimab BLA PDUFA date extended from Sep 25, 2025 to Dec 26, 2025; labeling discussions planned by Oct 2025.","Advanced partnership discussion: potential multi-billion transaction value excl. royalties; upfront would repay $67.1M term loan and $17.1M notes.","Cash and equivalents $26.0M as of July 18; 61.8M shares outstanding.","PDE7 inhibitor program: preclinical studies for cocaine use disorder completed; FDA requests more preclinical info."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135103,"accession_number":"0001437749-25-021959","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Omeros shareholders elect directors, approve say-on-pay, ratify Ernst & Young","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arnold C. Hanish elected Class I director with 16,033,755 for, 1,245,397 against.","Rajiv Shah, M.D. elected Class I director with 16,198,053 for, 946,241 against.","Advisory say-on-pay approved: 15,086,368 for, 1,856,643 against, 615,511 abstain.","Ernst & Young ratified as auditor for FY25: 41,204,073 for, 1,237,033 against.","Total shares represented at meeting: 42,725,983 (72.92% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152078,"accession_number":"0001437749-25-017426","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K/A","filed_at":"2025-05-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Omeros files 8-K/A to correct omitted table in Second Supplemental Indenture","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment filed solely to replace Exhibit 4.2 with corrected version including missing table.","Second Supplemental Indenture dated May 14, 2025 with Computershare Trust Company as trustee.","No other changes made to the original May 15, 2025 Current Report or to Exhibit 4.2.","Error stemmed from processing issue with embedded table; financial terms unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152080,"accession_number":"0001437749-25-017211","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.","Cash and short-term investments $52.4M at Mar 31, 2025, down $37.7M from Dec 31, 2024.","Exchanged $70.8M of 5.25% 2026 notes for new 9.50% 2029 notes; additionally $10M notes converting to equity.","Outstanding 2026 notes reduced to ~$17.1M; avoids $20M term loan prepayment plus $1M premium due Nov 2025.","FDA accepted BLA for narsoplimab in TA-TMA; PDUFA date Sep 25, 2025. Phase 3 PNH program paused to conserve cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152079,"accession_number":"0001437749-25-014815","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.","Resubmission includes survival analyses comparing narsoplimab-treated patients to external control, showing statistically significant improvement.","Also includes data from expanded access program in adult and pediatric TA-TMA patients.","Omeros is preparing MAA for submission to European Medicines Agency later this quarter.","Company responding to FDA information requests; expects interactive review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170899,"accession_number":"0001437749-25-010211","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.","Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.","OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.","BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.","Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170898,"accession_number":"0001437749-25-004505","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.","Previously untreated high-risk adults: 1-year survival 58%; children: 79% in EAP.","Refractory patients (failed complement inhibitors): 1-year survival 44% vs historical <20%.","No safety signals; BLA resubmission expected later Q1 2025, MAA submission by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170897,"accession_number":"0001437749-25-001245","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.","Primary endpoint (Dec 19): HR=0.32 (95% CI 0.23–0.44), p<0.00001, over 3-fold mortality reduction in TA-TMA patients.","Omeros targets BLA resubmission to FDA later this quarter and European MAA submission by mid-year.","Narsoplimab has been well tolerated across trials with no safety signal of concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187866,"accession_number":"0001437749-24-037898","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.","Omeros will resubmit the narsoplimab BLA to FDA as soon as possible for first approved TA-TMA therapy.","Expanded access program data: 46% of adults and 50% of children achieved TA-TMA resolution after failing C5 inhibitors.","European marketing authorisation application planned for Q2 2025; additional sensitivity analyses and manuscripts expected early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187865,"accession_number":"0001437749-24-034900","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.","Cash and investments $123.2M at Sept 30, down $48.7M from Dec 31, 2023, including $18.4M narsoplimab drug substance charge and $21.2M debt repurchase.","Narsoplimab in TA-TMA: FDA presubmission in Sep 2024; minor feedback on statistical plan incorporated; BLA resubmission planned after efficacy analysis; European MAA in H1 2025.","Zaltenibart (OMS906): FDA and EU regulators agree on Phase 3 design for PNH; enrollment expected early 2025; rare pediatric disease designation for C3G.","OMIDRIA royalties $9.3M on Rayner’s U.S. sales $31.0M in Q3 2024 vs $10.0M on $33.3M in Q3 2023."],"consensus_eps_estimate":-0.4539,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204389,"accession_number":"0001437749-24-025179","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.","Entered $67.1M secured term loan with Athyrium/Highbridge; repurchased $118.1M of 5.25% 2026 notes at ~25% discount.","Cash and investments $158.9M at June 30; OMIDRIA royalties $10.9M on Rayner net sales $36.4M.","FDA meeting scheduled for narsoplimab BLA resubmission in TA-TMA; Phase 3 for zaltenibart in PNH on track for late 2024.","Zaltenibart Phase 2 data: mean hemoglobin improvement 3.27 g/dL; 10/12 patients advanced to monotherapy."],"consensus_eps_estimate":-0.4906,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221153,"accession_number":"0001437749-24-020102","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Omeros CFO Jacobsen retiring June 30; Borges appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael A. Jacobsen retires as VP Finance, CAO & Treasurer effective June 30, 2024; stays as part-time advisor at $5k/month.","David J. Borges named VP Finance, CAO & Treasurer effective June 30; base salary $325k, target bonus 35%.","Annual meeting elects directors Bumol, Demopulos, Hood; say-on-pay passes with 15.85M for vs 6.98M against.","Ratification of Ernst & Young as auditor for FY2024 approved by 41.81M votes.","Borges joined Omeros in 2020; prior roles at Merck and Bulletproof 360; CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221152,"accession_number":"0001437749-24-018964","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.","Used $67.1M loan and $21.2M cash to repurchase $118.1M (55%) of 5.25% convertible notes due 2026, resulting in $51M debt extinguishment.","Non-dilutive transaction; no equity component. Loans mature June 3, 2028, with interest at SOFR (3% floor) + 8.75% per annum.","Credit agreement requires maintaining ≥$25M unrestricted cash; additional repurchases of 2026 notes permitted under limitations.","After repurchase, $97.9M of 2026 notes outstanding; Omeros retains flexibility to exchange up to $16.9M notes for cash and additional term loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221151,"accession_number":"0001437749-24-017044","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.","Cash + short-term investments $230.3M at Mar 31, up $58.5M from Dec 31; includes $115.5M from DRI royalty deal.","Sold DRI expanded OMIDRIA royalty: DRI gets all US royalties through 2031; Omeros retains ex-US & post-2031 global; potential milestones up to $27.5M each.","OMS906 Phase 2 PNH data at EHA June 15; Phase 3 start late 2024. Narsoplimab BLA resubmission timeline uncertain pending FDA.","Repurchased 3.2M shares for $11.9M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221150,"accession_number":"0001437749-24-010359","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.","Amended OMIDRIA royalty deal with DRI: received $115.5M; DRI gets all U.S. royalties through 2031; Omeros retains ex-U.S. & post-2031 global royalties; potential $55M milestones.","Cash and investments $171.8M at Dec 31, 2023; plus $115.5M from DRI in Feb 2024; expects ~$230M at Mar 31, 2024 after share repurchases.","Narsoplimab BLA resubmission in TA-TMA still under FDA discussion; unable to estimate timing for submission or approval.","OMS906 Phase 2 trials in PNH fully enrolled; positive interim data; Phase 3 targeted late 2024; OMS1029 Phase 1 multiple-ascending dose completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240730,"accession_number":"0001437749-24-003287","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Omeros amends royalty deal with DRI, receives $115M for expanded OMIDRIA royalty sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Omeros received $115M cash from DRI Healthcare Acquisitions LP for an expanded interest in OMIDRIA royalties.","Amendment eliminates annual caps on DRI royalties; DRI now receives all U.S. net sales royalties from Jan 2024 through Dec 2031.","Omeros eligible for two milestone payments of up to $27.5M each in Jan 2026 and Jan 2028 based on U.S. sales thresholds.","Omeros retains all non-U.S. OMIDRIA royalties from Jan 2024 and all global royalties after Dec 2031; royalty term extends to 2035 in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258230,"accession_number":"0001437749-23-031249","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.","OMIDRIA royalties $10.0M on $33.3M US sales (down from $16.5M) due to royalty rate drop to 30%.","$310.3M cash as of Sept 30; expects to repay $95M convertible notes due Nov 15, 2023.","Phase 3 ARTEMIS-IGAN trial for IgA nephropathy discontinued after interim analysis missed primary endpoint.","BLA resubmission for narsoplimab in TA-TMA on track for FDA decision mid-2024; OMS906 Phase 2 PNH data pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258229,"accession_number":"0001437749-23-028296","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).","Placebo group showed markedly greater proteinuria reduction than in other IgA nephropathy trials.","Company will not submit BLA for narsoplimab in IgAN and is discontinuing the ARTEMIS-IGAN trial.","Funds redirected to OMS906 (alternative pathway inhibitor) Phase 2/3 programs and narsoplimab BLA resubmission for HSCT-TMA.","Narsoplimab was generally well tolerated with no new safety concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275544,"accession_number":"0001558370-23-014088","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.","OMIDRIA royalties $10.7M on Rayner sales $35.7M; rate cut from 50% to 30% after $200M milestone.","Cash, equivalents, and short-term investments $341.3M; accounts receivable $11.2M; runway into 2025.","FDA Type B meeting; plan to submit detailed survival data analysis for narsoplimab BLA in TA-TMA; target mid-2024 decision.","Phase 3 ARTEMIS-IGAN IgA nephropathy 9-month data expected later Q3 2023; OMS906 PNH trial shows positive interim results."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293047,"accession_number":"0001558370-23-011533","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Omeros shareholders approve 5M share increase in incentive plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas J. Cable, Peter A. Demopulos, M.D., and Diana T. Perkinson, M.D. elected as Class II directors with majority votes.","Shareholders approved amendment to 2017 Incentive Plan, increasing authorized shares by 5M to total 17.6M shares.","Advisory vote on executive compensation passed; board sets annual frequency for future say-on-pay votes.","Ernst & Young ratified as independent auditor for FY2023 with 43.3M votes for, 1.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293046,"accession_number":"0001558370-23-010058","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Omeros appoints Dr. Diana T. Perkinson to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to nine; Dr. Perkinson appointed effective May 12, 2023.","Perkinson is a physician with board certifications in nephrology and internal medicine.","Appointed to scientific committee; granted option to purchase 30,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293045,"accession_number":"0001558370-23-008805","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.","Received $200M milestone from Rayner; OMIDRIA royalties $9.2M on $30.7M sales (down from $13.8M on $27.7M).","Plans BLA resubmission for narsoplimab in TA-TMA; meeting with FDA this month.","OMS906 in PNH: mean Hgb increased 3.4 g/dL at day 29; 100% of patients Hgb >=15.7 g/dL at day 113.","Awarded $6.69M NIDA grant for OMS527 in cocaine use disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313701,"accession_number":"0001558370-23-003572","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.","Received $200M milestone from Rayner in Feb 2023; OMIDRIA Q4 royalties $17.9M on record $35.8M sales.","Cash and short-term investments $194.9M; accounts receivable $213M now collected; no SVB exposure.","Preparing narsoplimab BLA resubmission for TA-TMA; FDA meeting expected Q2 2023; ARTEMIS-IGAN data Q3 2023.","Initiated OMS906 trials in PNH (treatment-naïve and ravulizumab inadequate response) and C3G; OMS1029 quarterly dosing possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313700,"accession_number":"0001558370-23-000894","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.","Omeros ended 2022 with ~$195M cash; combined with $200M milestone provides funding into at least 2025.","2022 U.S. net sales of OMIDRIA totaled $131M; CAA 2023 secures separate payment for non-opioid pain drugs through Jan 2028.","Proceeds to fund R&D, manufacturing, potential acquisitions; may retire convertible notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332167,"accession_number":"0001558370-22-017140","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros reports Q3 2022 net loss $17.5M; FDA denies narsoplimab appeal, provides resubmission path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.5M ($0.28/share) vs $22.7M loss in 3Q21; cash and equivalents $221M at Sept 30.","FDA denied Formal Dispute Resolution for narsoplimab BLA; proposes resubmission with survival vs historical control.","Sold interest in OMIDRIA royalties to DRI for $125M cash; max DRI payout $188.4M at 9.4% effective rate.","CMS final rule confirms separate OMIDRIA payment in ambulatory surgical centers for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332166,"accession_number":"0001558370-22-014884","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Omeros sells portion of OMIDRIA royalties for $125M; total capped payments of $188.4M through 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $125M upfront from DRI Healthcare for partial sale of OMIDRIA royalties.","DRI gets capped payments: $1.67M in 2022, $13M in 2023, $20M in 2024, $25M/yr 2025-28, $26.25M 2029, $27.5M 2030.","Total payments to DRI capped at $188.4M; Omeros retains royalties above annual caps.","No recourse to Omeros assets beyond purchased receivables; no financial covenants.","Agreement terminates Dec 31, 2030 or when DRI receives all payments due."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349633,"accession_number":"0001558370-22-012871","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros reports Q2 2022 net loss $30.9M; narsoplimab FDA dispute decision expected August","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Royalties of $17.2M on OMIDRIA sales of $34.5M, a new all-time high.","Net loss $30.9M ($0.49/share) vs $28.6M ($0.46/share) in Q2 2021.","Cash and short-term investments $122.6M as of June 30, down $19.7M from Q1.","Submitted Formal Dispute Resolution to FDA for narsoplimab in TA-TMA; decision expected in August 2022.","OMS906 received orphan drug designation for PNH; Phase 1b trials expanding to treatment-naïve and C3G patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366642,"accession_number":"0001558370-22-010283","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Omeros holds 2022 annual meeting; shareholders re-elect two directors and ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Arnold C. Hanish re-elected as Class I director with 17.5M for, 8.6M against, 0.9M abstain.","Rajiv Shah, M.D. re-elected as Class I director with 19.2M for, 7.0M against, 0.9M abstain.","Ernst & Young LLP ratified as auditor for FY2022 with 44.4M for, 2.3M against, 0.4M abstain.","Meeting had 75.07% of outstanding shares represented (47.1M of 62.7M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366641,"accession_number":"0001558370-22-008110","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.","Royalty revenue of $13.8M from Rayner's OMIDRIA sales ($27.7M, all U.S.); up from $21.1M prior Omeros net sales.","Cash, equivalents, short-term investments $142.2M at March 31, 2022; down $15M from Dec 2021.","FDA denied narsoplimab BLA (TA-TMA); Omeros plans formal dispute resolution within weeks.","Enrollment expected summer 2022 for Phase 1b OMS906 (PNH) and Phase 1 OMS1029 (long-acting MASP-2)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386064,"accession_number":"0001558370-22-002558","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.","Adjusted Q4 net loss excluding OMIDRIA divestiture would have been $23.0M ($0.37/share) vs Q3 loss $22.7M ($0.36/share).","Completed sale of OMIDRIA to Rayner Surgical on Dec 23, 2021 for $126M cash; Omeros retains 50% US royalty until $200M milestone then 30% thereafter.","Received FDA Complete Response Letter for narsoplimab BLA in TA-TMA in Oct 2021; held Type A meeting in Feb 2022, awaiting FDA response.","Cash and short-term investments $157.3M at Dec 31, 2021 plus $38.2M accounts receivable expected to be collected in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":3.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403976,"accession_number":"0001558370-21-017078","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Omeros closes $126M OMIDRIA sale to Rayner; deal valued >$1B including royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received ~$126M cash at closing; retains accounts receivable.","Eligible for $200M milestone if separate OMIDRIA payment secured for 4 consecutive years before 2025.","US royalty: 50% of net sales until milestone/2025, then 30% through patent life (2032).","Ex-US royalty: 15% of net sales on country-by-country basis.","Transaction removes OMIDRIA revenue and costs from continuing ops; pro forma shows ongoing R&D and SG&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403975,"accession_number":"0001104659-21-145685","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-12-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Omeros sells OMIDRIA franchise to Rayner Surgical for $125M upfront plus milestones and royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $125M at closing; potential $200M milestone if separate payment secured for four continuous years.","Royalties: 50% of U.S. net sales until earlier of Jan 1, 2025 or milestone paid, then 30%; 15% on ex-U.S. net sales.","Transaction valued in excess of $1 billion including royalties; Omeros retains $34M accounts receivable.","Omeros to focus on complement franchise of MASP-2 and MASP-3 inhibitors.","Closing expected on or before Dec 31, 2021, subject to HSR waiting period expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403974,"accession_number":"0001558370-21-015276","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.","Net loss $22.7M ($0.36/sh) improved from $28.6M ($0.46/sh) in Q2; cash $50.4M.","CMS confirmed separate payment for OMIDRIA in ASC for 2022; NOPAIN Act has 34 Senate/74 House sponsors.","Received FDA Complete Response Letter for narsoplimab BLA in HSCT-TMA; preparing Type A meeting.","Phase 1 data for OMS906 shows high alternative pathway suppression; moving directly into PNH patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":79889000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403973,"accession_number":"0001558370-21-013245","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-10-18T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Omeros receives FDA Complete Response Letter for narsoplimab BLA; director Ray Aspiri retires","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Ray Aspiri retired from Omeros board effective Oct 14, 2021, with no disagreement with the company.","FDA issued a Complete Response Letter for narsoplimab BLA for HSCT-TMA, citing difficulty estimating treatment effect.","FDA stated additional information is needed to support regulatory approval of narsoplimab for HSCT-TMA.","No CMC, safety, or non-clinical issues precluding approval were raised in the FDA Complete Response Letter.","Omeros plans to request a Type A meeting with FDA to discuss the most expeditious path for narsoplimab approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403972,"accession_number":"0001558370-21-012911","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Omeros receives FDA deficiency notice for narsoplimab BLA; PDUFA date expected to be missed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA identified deficiencies in narsoplimab BLA for HSCT-TMA, precluding labeling/post-marketing discussions.","Resolution not expected by Oct 17, 2021 PDUFA target action date; FDA expressed intent to work with Omeros.","No specific deficiencies disclosed; Omeros evaluating next steps for HSCT-TMA, a lethal condition with no approved therapy.","Narsoplimab has Breakthrough Therapy and Orphan designations; first BLA submitted for HSCT-TMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422941,"accession_number":"0001558370-21-010964","cik":1285819,"company_name":"OMEROS CORP","ticker":"OMER","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.","Narsoplimab BLA for HSCT-TMA under FDA priority review with PDUFA action date Oct 17, 2021.","Preliminary Phase 1 data for OMS906 (MASP-3 inhibitor) show well tolerated, PK/PD consistent with monthly SC dosing.","CMS proposed rule reaffirms separate payment for OMIDRIA in ASCs for 2022.","Cash & investments $73.7M; $150M ATM program available; $50M line of credit."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":49885000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":797576345.5519421,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-09T23:59:59+00:00|422941"}